Molecular Vision 2013; 19:333-347 <>
Received 22 August 2012 | Accepted 05 February 2013 | Published 07 February 2013

Contribution of the latent transforming growth factor-beta binding protein 2 gene to etiology of primary open angle glaucoma and pseudoexfoliation syndrome

Sahar Jelodari-Mamaghani,1 Ramona Haji-Seyed-Javadi,1 Fatemeh Suri,1 Naveed Nilforushan,2 Shahin Yazdani,3 Kambiz Kamyab,4 Elahe Elahi1,5

The first two authors contributed equally to this work.

1School of Biology, University College of Science, University of Tehran, Tehran, Iran; 2Eye Research Center, Rassoul Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran; 3Ophthalmic Research Center, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 4Department of Pathology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran; 5Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran

Correspondence to: Elahe Elahi, University College of Science, University of Tehran Phone: 00989122181251; FAX: 00982166405141; email:


Purpose: To assess for the first time the possible contribution of latent transforming growth factor (TGF)-beta binding protein 2 (LTBP2), an extracellular matrix (ECM) protein that associates with fibrillin-1-containing microfibrils, to the etiology of primary open angle glaucoma (POAG) and pseudoexfoliation (PEX) syndrome. Mutations in LTBP2 have previously been shown to be the cause of primary congenital glaucoma (PCG) and other disorders that often manifest as secondary glaucoma.

Methods: All exons of LTBP2 were sequenced in the DNA of 42 unrelated patients with POAG and 48 unrelated patients with PEX syndrome. Contribution of candidate variations to disease was assessed by screening in control individuals and use of biochemical, bioinformatics, and evolutionary criteria, and in one case by segregation analysis within the family of a proband with POAG. Microscopy was performed on the skin of a patient with PEX syndrome whose condition developed into PEX glaucoma during the course of the study and on the skin of her son previously identified with PCG who harbored the same LTBP2 mutation.

Results: Among the 30 sequence variations observed in LTBP2, five found in five patients with POAG and two found in two patients with PEX glaucoma syndrome may contribute to their diseases. One of the mutations was observed in a patient with POAG and in a patient with PEX glaucoma syndrome. Light, fluorescent, and electron microscopy showed that a mutation present in one of the individuals affected with PEX glaucoma syndrome and in her son affected with PCG causes disruptions in the ECM.

Conclusions: Some LTBP2 sequence variations can contribute to the etiology of POAG and PEX glaucoma syndrome. It is not expected that in these diseases LTBP2 mutations behave in a strictly Mendelian fashion with complete penetrance. In conjunction with recent findings, the results suggest that anomalies in the ECM are among the factors that can contribute to POAG and PEX glaucoma syndrome. LTBP2 and other related ECM protein coding genes should be screened in larger cohorts with these diseases, which are common disorders and important to the public health.


LTBP2 (OMIM 602091), the gene encoding latent transforming growth factor (TGF)-beta binding protein 2, was identified in 2009 as a gene causing primary congenital glaucoma (PCG; OMIM 231300) [1,2]. More recently, it was shown that LTBP2 mutations can also cause megalocornea [3,4], microspherophakia [5], and Weill-Marchesani syndrome (WMS; OMIM 277600) and promote Marfan syndrome (MFS; OMIM 154700) features [6]. The possible contribution of LTBP2 to primary open angle glaucoma (POAG; OMIM 137760) and pseudoexfoliation syndrome (PEX; OMIM 177650) is addressed in this study. LTBP2 on chromosome 14 encodes an extracellular matrix (ECM) protein that is a member of a superfamily composed of multiple fibrillin and LTBP proteins [7,8]. LTBP2 is expressed in elastic tissues and associates with fibrillin-1-containing microfibrils [9]. It is believed that LTBP2 has functions related to those of microfibrils and elastic fibers. In addition to structural roles, it may affect TGF-β activities.

Glaucoma, the second leading cause of blindness, is a heterogeneous group of optic neuropathies that manifest by optic nerve head cupping or degeneration of the optic nerve, resulting in a specific pattern of visual field loss [10]. Increased intraocular pressure (IOP) is often associated with the condition. The disease is sub-grouped based on etiology, anatomy of the anterior chamber, and age at onset [10]. POAG accounts for 70% of glaucoma cases in Caucasian populations and usually affects individuals past the age of 40 [11]. In this form of glaucoma, the anterior chamber angle appears normal; this form is associated with variable severity and phenotypic expressivity [12,13]. Although POAG in some families demonstrates Mendelian inheritance, the disease usually presents as a complex disease. After identifying LTBP2 as a PCG causative gene, the authors considered the gene might also cause POAG [1,2]. A POAG locus (LOD scores of 3.99) on chromosome 14q has been reported in a linkage study [14]. Cytogenetic studies have also suggested a tentative link between 14q and glaucoma [15,16]. Furthermore, a quantitative trait locus for high IOP, a prominent feature of glaucoma, has been reported on 14q [17]. In addition, mutations in the PCG causative gene CYP1B1 have been observed in patients with POAG, and it was thought that other genes including LTBP2 may also have roles in the etiology of both diseases [18-20]. Finally, all the disorders so far identified that can be caused by mutations in LTBP2 often manifest secondary glaucoma.

Pseudoexfoliation (PEX) syndrome is a common disorder that usually affects elderly individuals [21]. It is often accompanied by glaucoma and is in fact one of the most common causes of glaucoma. PEX syndrome is considered a fibrotic matrix disorder, characterized by stress-induced elastosis and excessive production and abnormal cross-linking of elastic microfibrils [22]. Aggregates in the form of what is known as PEX material deposit mainly in the anterior segment of the eye. PEX material consists of various elastic and microfibril-related proteins, including fibrillin-1 and LTBP2. Given that PEX is a fibrotic disorder often associated with glaucoma (PEXG) and that LTBP2 is a component of PEX material, the possibility that LTBP2 mutations may be associated with this disease was also considered.

We performed mutation screening of LTBP2 in a cohort of 90 patients with POAG or PEX syndrome. To the best of our knowledge, this is the first time LTBP2 has been screened in patients with these disorders. Sequence variations were found in both types of patients, and the properties of the variations support the proposition that LTBP2 may have a role in the etiology of these diseases. Microscopic examination of skin fibroblasts of two patients with LTBP2 mutations showed notable disruption of the ECM. Our results emphasize that the ocular anomalies in some patients with POAG and PEX can be due to disruptions in the ECM.


This study was performed in accordance with the Declaration of Helsinki and with approval of the ethics board of the University of Tehran. All participants or their responsible guardians consented to participate after being informed of the nature of the research.


Forty-two and 48 Iranian individuals with POAG and PEX syndrome, respectively, were recruited from the Ophthalmology Department of Labbafinejad Medical Center (associated with Shahid Beheshti University of Medical Sciences) and Hazrat Rassoul Hospital (associated withTehran University of Medical Sciences). The patients did not report symptoms of other disorders at the time of recruitment, except one patient (211L) who reported a cardiac anomaly as described below. None of the 90 patients were related. As will be described, one of the patients with PEX syndrome was the mother of a patient with PCG examined in a previous study [2]. The patients were recruited consecutively, without regard to disease presentation being apparently sporadic or familial and without regard to age at onset. Sex was distributed almost equally in each group of patients. All patients with POAG (range 19-76 year; average: 54) and PEX syndrome (range 62-83 year; average: 76) syndrome were diagnosed by one or two glaucoma specialists (N.N. and S.Y.). Slit-lamp biomicroscopy, IOP measurement, gonioscopy, fundus examination, and perimetry were performed. Perimetry was performed at least two times in all patients with POAG and PEX syndrome harboring putative disease contributing variations. IOP measurements were obtained using Goldmann applanation tonometry. Criteria for diagnosis of POAG were the presence of at least two of the following criteria: an IOP greater than 21 mmHg in at least one eye or inter-eye IOP asymmetry exceeding 8 mmHg; characteristic glaucomatous optic nerve head or retinal nerve fiber layer (RNFL) changes (e.g., vertical cupping, neural rim thinning or loss, RNFL dropout); and visual field defects not attributable to other causes. None of the patients with diagnosed POAG had other ocular anomalies, and all presented with an open anterior chamber angle in the affected eyes. Furthermore, all patients with POAG were screened for mutations in MYOC and CYP1B1 as previously described, and only those without disease-associated mutations in these genes were screened for variations in LTBP2 [18]. After genetic screening, attempts were made to obtain familial data from the patients with POAG in whom candidate disease-contributing sequence variations were observed.

PEX syndrome diagnosis was based on observation of PEX material on the anterior lens capsule and/or pupillary margin after mydriasis by slit lamp biomicroscopy [23]. Secondary open angle glaucoma in patients with PEX syndrome was diagnosed as described for POAG. Thirty-three (70%) of the patients with PEX presented with secondary glaucoma (patients with PEXG). Four hundred Iranian unrelated control individuals older than 60 years of age without self-reported family history of ocular diseases were also recruited.

Latent transforming growth factor-beta binding protein 2 gene screening

LTBP2 exons and flanking intronic sequences were amplified with PCR, and subsequently sequenced with the Sanger protocol [2]. The LTBP2 reference sequences used were NT_026437.12, NM_000428.2, and NP_000419.1. The effects of the variant sequences on splicing were predicted by using NNSPLICE 0.9, Human Splicing Finder V 2.4.1 and GENSCAN. Potential effects of all variations on splicing, including those that affected amino acid changes, were checked. To determine the extent of the conservation of amino acids altered due to nucleotide variations, the amino acid sequences of homologous proteins from other species were aligned using the ClustalW2 software. Variations deemed to contribute to disease status were assessed in control individuals with allele-specific PCR protocols or restriction fragment length polymorphism analysis. The number of control individuals screened differed for the different variations and ranged from 200 to 400 (Table 1). The structural consequences of these variations were predicted using the PolyPhen-2 in silico tool [24]. The sequences of all primers used to amplify the LTBP2 exons are available in supplementary Appendix 1.


To assess the effect of an LTBP2 mutation observed in a patient with PEX syndrome and previously observed in related patients with PCG, the ECM of skin fibroblasts from patients harboring the mutation was examined using light, immunofluorescent, and electron microscopy. A skin tissue specimen with a depth of approximately 6 mm was obtained from behind the ears of these patients and age- and sex-matched control individuals. The specimens were cut into portions and placed in glutaraldehyde or tissue freezing medium. One glutaraldehyde-fixed sample from each individual was processed for staining with Orcein Giemsa to stain elastin and with Trichrome to stain collagen. For immunofluorescent staining, cryosections were incubated with goat polyclonal antibody against human LTBP2 (LTBP2 (N20), Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or rabbit polyclonal antibody against human fibrillin-1 (ab53076, Abcam, Cambridge, England). Negative controls were not incubated with primary antibody. The sections were subsequently incubated with fluorescent conjugated secondary antibodies (Santa Cruz Biotechnology). Nuclei in the same sections were counterstained with 4’, 6-diamidino-2-phenylindole (Invitrogen, Carlsbad, CA). Finally, samples were processed for electron microscopy, and 60 nm sections were visualized with a Zeiss EM900 transmission electron microscope (Carl Zeiss, Jena, Germany).


Thirty LTBP2 sequence variations were observed in the 90 individuals screened (Appendix 2). Nineteen are previously reported variations, and 11 are novel variations. The allele frequency of 18 of the non-novel variations as reported in the Single Nucleotide Polymorphism Database (dbSNP) ranged from 0.012 to 0.405. The dbSNP data incorporates data derived from the 1000 Genomes Project. Six of the novel variations were observed in controls, created synonymous codons, were not highly conserved during evolution, and/or were intronic variations predicted not to affect splicing. We opted for a conservative approach and considered that these 24 variations did not contribute to disease status; clearly, variations reported in databases and variations observed in controls may predispose individuals to disease, particularly common and late onset diseases such as POAG and PEX syndrome. A previously identified PCG causative mutation and five novel variations were considered reasonable candidates for being variations or risk factors contributing to POAG and/or PEX. All but one were observed in the heterozygous state. Considerations including position of the affected amino acid within the protein, the biochemical nature of the amino acid change, the bioinformatics prediction of the effect of the change, the extent of the evolutionary conservation, and absence in controls were taken into account in making this assessment (Figure 1 and Figure 2). Segregation with disease status and familial data were also considered for one variation (p.Arg495Gln). All the novel variations and data evidencing disease association or absence of disease association are presented in Table 1 and Appendix 3. LTBP2 protein sequence alignments that allow assessment of evolutionary conservation are presented in Appendix 4. The position of candidate disease-influencing variations and previously reported mutations within the LTBP2 protein are presented in Figure 3. Some features of the variations observed in this study are described further.

Five novel coding variations in LTBP2 assessed as causing or as risk factors for disease were observed in five of the 42 patients with POAG screened (Table 1). Clinical features of the five patients are presented in Appendix 5. Age at onset in the patients harboring these putative POAG-contributing mutations ranged from 22 to 70 years. P.Pro432Leu among these was also observed in a patient with PEXG. The variation affecting p.Arg495Gln was observed in two siblings with POAG (Figure 4A,B). A fundus image of an eye of the proband showing features that confirm a diagnosis of glaucomatous optic neuropathy and results of perimetry showing visual field loss are presented in Figure 4C and Figure 5, respectively. Age at onset of the two sisters was 20 and 22 years. Furthermore, the deceased father and grandfather had had glaucoma and had become blind in one or both eyes in the third decade of their lives. Genetic analysis showed that the mother carried wild-type alleles, and clinical examination showed that she was free of ocular anomalies. The nucleotide sequence variation that caused p.Arg495Gln was not observed in 400 unaffected elderly ethnically matched control individuals. Interestingly, both siblings and also another POAG patient (213R) with an LTBP2 mutation had the same cardiac anomalies that had previously been attributed to LTBP2 mutations in WMS and MFS pedigrees [6]. The variation affecting p.Gln1417Arg was the only putative POAG-contributing variation found that occurred in the homozygous state (Table 1).The parents, who are deceased, were first cousins. Of the five patients who harbored the novel coding variations, all except the patient with the variation that caused p.Arg495Gln were apparently sporadic as they reported they were the only known individual with POAG in the respective families.

Among the 15 patients with PEX and 33 patients with PEXG, four novel coding variations were observed that were not found in controls (Table 1). The variations affecting p.Ile667Leu and p.Met1567Val, though novel and rare (not observed in 200 controls), are probably not associated with disease (Table 1). The variations that caused p.Pro432Leu and p.Tyr1792fsX55 likely contribute to the disease status of the patients with PEX syndrome. P.Pro432Leu is the variation also observed in a patient with POAG. The difference in the frequency of the causative variation in the patients (2/180 chromosomes) and the controls (0/800 chromosomes) is statistically highly significant (p=0.003). The patient with PEX syndrome who carried the p.Tyr1792fsX55-causing mutation in the heterozygous state was the mother of the proband (individual 21) of the PCG pedigree in which LTBP2 was identified as a PCG causative gene [2]. Observation of PEX syndrome in a heterozygous carrier and PCG in a homozygous carrier of the same mutation was intriguing. Histology was performed to get some insight into the effects of the mutation and the differential effects in the two individuals. Skin tissue was used because access to ocular tissue was not feasible. Light, electron, and fluorescent microscopy shown abnormalities in the ECM of both patients (Figure 6, Figure 7, and Figure 8). In the light microscope images, the elastic fibers were sparser and fragmented in each patient compared to the respective control (Figure 6A–D). In general, disruption of the elastic fibers appeared more severe in the patient with PCG (Figure 6A) compared to his mother with PEX syndrome (Figure 6B), who was 55 years old and 25 years older than her son. Collagen fibers were also sparser in each patient compared to the respective control (Figure 6E–H). Finally, electron micrographs also clearly showed that the ECM of each patient was sparser than that of the controls (Figure 7A compared to Figure 7C, and Figure 7B compared to Figure 7D), and that the ECM of the patient with PCG was more severely disrupted than the ECM of the patient with PEX syndrome (Figure 7A compared to Figure 7B). Antibodies against LTBP2 and fibrillin-1-stained fibers that were longer and thicker in the ECM of the control individuals (Figure 8 and Figure 9). The fibers were sparse in the patient with PCG, but dense and convoluted in the ECM of the patient with PEX syndrome. This appearance is characteristic of microfibrils in patients with PEX syndrome [25]. The patterns described were consistently observed in multiple sections from the individuals studied. When the mother was examined in early 2011, she was diagnosed with PEX syndrome without glaucoma. Upon reexamination in 2012, her presentation had evolved into PEXG syndrome. Images of the eyes of the mother with PEXG syndrome and the son with PCG are shown in Figure 10. Depositions of PEX material and glaucomatous damage are evident in the mother’s eye.


Mutations in LTBP2 have previously been shown to cause several disorders, all of which have ocular manifestations, and one of the ocular manifestations is often glaucoma [1-5]. Contrary to other known genes causing PCG (CYP1B1) or POAG (MYOC, OPTN, and WDR36), one can easily consider a plausible cellular and molecular basis for association between LTBP2 and the glaucoma phenotype. LTBP2 is an extracellular matrix microfibril protein, and defects in the ECM of the trabecular meshwork may affect facility of aqueous fluid outflow resulting in increased IOP [26]. This notwithstanding, the consequences of LTBP2 mutations for regulating TGF-β signaling may also be relevant to the etiology of glaucoma. Five putative disease-contributing or risk factor mutations in LTBP2 were observed among 42 patients with POAG without CYP1B1 and MYOC mutations. Although the size of the cohort screened was small, the frequency of the observed LTBP2 mutations compares well with that of other known genes causing POAG [18,27]. Relevant to this finding, ADAMTS10 was recently reported as a POAG causative gene in a canine model of the disease [28]. ADAMTS10 is a member of a disintegrin and metalloproteinase with thrombospondin motifs family of secreted proteases that similarly to LTBP2 is involved in the formation of the ECM [29]. Both proteins are expressed in the trabecular meshwork [2,28]. POAG rarely exhibits Mendelian inheritance, and many genetic and possibly non-genetic factors contribute to its pathogenesis. Taken together, the data presented here support the proposal that structural and/or functional defects of the ECM and/or microfibrils are among the factors that contribute to POAG and that mutations in genes coding for various components of the ECM and microfibrils including LTBP2 are implicated in the disease’s etiology. ECM abnormalities have also previously been suggested to affect IOP elevation in glaucoma [30-33].

PEX syndrome is a fibrillinopathy that can present with numerous clinical complications [34]. Ocular tissues are most commonly affected. In addition to LTBP2 being a component of PEX material, there is increased TGF-β and LTBP2 in the aqueous fluid of affected individuals [25]. In addition, LTBP2 and FBN1 were identified as upregulated genes in anterior segment eye tissues of individuals with PEX [35]. The role of TGF-β1 in the pathogenesis of PEX has been emphasized, and it was suggested that LTBP2 via its effects on TGF-β activation may be involved in the disease process [25]. Variable incidence of PEX in different populations and increased risk in relatives of affected individuals indicate a genetic component in the disease’s etiopathogenesis, but knowledge of the genetics of PEX is rudimentary [22]. Association between some single nucleotide polymorphisms in LOXL1 encoding lysyl oxidase-like 1 and PEX syndrome has been reported, although the PEX-associated variants in LOXL1 exhibit low penetrance [36-38]. Lysyl oxidase-like 1 is a cross-linking enzyme with functions in elastic fiber formation and stabilization [39]. Here, we report the presence of two putative LTBP2 mutations in patients with PEX. One mutation affected p.Pro432Leu and was observed in a patient with PEXG. The fact that it was also observed in a patient with glaucoma argues in favor of its pathogenicity. The second mutation caused p.Tyr1792fsX55 and was observed in a patient with PEXG; the same mutation in the homozygous state caused PCG in other family members. It was absent in 400 control individuals over the age of 60 without eye disorders. Penetrance of the p.Tyr1792fsX55-causing mutation regarding PEX is apparently incomplete because the father of the family who harbored the same mutation was diagnosed normal; he is now deceased. Histological analysis showed that the p.Tyr1792fsX55-causing mutation disrupted the ECM and microfibril structures, and that the disruptions were more severe in homozygous carriers of the mutation. Histological analysis in a patient with WMS who harbored a different mutation in LTBP2 also showed disruption of the ECM and microfibril structures. These findings further support the contention that LTBP2 mutations may contribute to various disorders with ocular manifestations by affecting the extracellular matrix.

There is variability in phenotypic consequences of mutations in LTBP2. A notable observation is that the mutation affecting p.Pro432Leu was observed in individuals with POAG and PEXG. The data presented here suggest that the penetrance of most observed LTBP2 mutations is incomplete as disease in the patients usually appeared sporadically. This is consistent with the common classification of POAG and PEX syndrome as complex disorders. As both diseases are multifactorial, factors in addition to the LTBP2 sequence variations affected disease status in the individuals harboring the mutation. Phenotypic presentations in individuals of the Roma/Gypsy population who harbored homozygous mutations causing p.Arg299X in LTBP2 were reported to range from PCG with trabecular meshwork dysgenesis to Marfan syndrome-like zonular disease and late onset angle closure glaucoma [40]. In another family study, the same p.Arg299X mutation was reported to cause a recessive ocular syndrome exhibiting megalocornea, spherophakia, and secondary glaucoma [3]. Homozygous LTBP2 mutations are likely to result in a more severe phenotype; homozygous mutations were reported to cause PCG and WMS, which are early onset diseases with more severe clinical manifestations than POAG and PEX syndrome, which are late onset diseases [1,2]. Notably, POAG and PEX are not considered recessively inherited diseases. Phenotypic variability associated with FBN1 mutations is also evident. As stated, mutations in FBN1 can cause simple ectopia lentis, MFS, WMS as well as other related disorders [41]. The mutation affecting p.Cys1223Tyr has been observed in patients with MFS [42] and Shprintzen-Goldberg syndrome [43]. The variations in phenotypic manifestations of mutations in the two related genes LTBP2 and FBN1 may be due to environmental, epigenetic, or stochastic events. More interesting, it is also likely that there are epistatic relationships between genes coding various components of the ECM. An intriguing possibility is that some ECM-related proteins may be able to compensate one another’s functions to different degrees.

In conclusion, we report that LTBP2 mutations may cause or be risk factors for POAG and PEX. The findings emphasize the importance of the extracellular matrix to biologic functions affected in these disorders. POAG and PEX syndrome are common disorders important to public health issues of most populations. It is of paramount importance that larger patient cohorts with these diseases be screened for mutations in LTBP2 and other related ECM protein coding genes to better quantify their contributions to the diseases.

Appendix 1.

Appendix 2.

Appendix 3.

Appendix 4.

Appendix 5.


We thank the patients and their family members for participating in the study. This research was funded by the Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences and the Eye Research Center, Tehran, Iran and Rassoul Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran.


  1. Ali M, McKibbin M, Booth A, Parry DA, Jain P, Riazuddin SA, Hejtmancik JF, Khan SN, Firasat S, Shires M, Gilmour DF, Towns K, Murphy AL, Azmanov D, Tournev I, Cherninkova S, Jafri H, Raashid Y, Toomes C, Craig J, Mackey DA, Kalaydjieva L, Riazuddin S, Inglehearn CF. Null mutations in LTBP2 cause primary congenital glaucoma. Am J Hum Genet. 2009; 84:664-71. [PMID: 19361779]
  2. Narooie-Nejad M, Paylakhi SH, Shojaee S, Fazlali Z, Rezaei Kanavi M, Nilforushan N, Yazdani S, Babrzadeh F, Suri F, Ronaghi M, Elahi E, Paisan-Ruiz C. Loss of function mutations in the gene encoding latent transforming growth factor beta binding protein 2, LTBP2, cause primary congenital glaucoma. Hum Mol Genet. 2009; 18:3969-77. [PMID: 19656777]
  3. Désir J, Sznajer Y, Depasse F, Roulez F, Schrooyen M, Meire F, Abramowicz M. LTBP2 null mutations in an autosomal recessive ocular syndrome with megalocornea, spherophakia, and secondary glaucoma. Eur J Hum Genet. 2010; 18:761-7. [PMID: 20179738]
  4. Khan AO, Aldahmesh MA, Alkuraya FS. Congenital megalocornea with zonular weakness and childhood lens-related secondary glaucoma - a distinct phenotype caused by recessive LTBP2 mutations. Mol Vis. 2011; 17:2570-9. [PMID: 22025892]
  5. Kumar A, Duvvari MR, Prabhakaran VC, Shetty JS, Murthy GJ, Blanton SH. A homozygous mutation in LTBP2 causes isolated microspherophakia. Hum Genet. 2010; 128:365-71. [PMID: 20617341]
  6. Haji-Seyed-Javadi R, Jelodari-Mamaghani S, Paylakhi SH, Yazdani S, Nilforushan N, Fan JB, Klotzle B, Mahmoudi MJ, Ebrahimian MJ, Chelich N, Taghiabadi E, Kamyab K, Boileau C, Paisan-Ruiz C, Ronaghi M, Elahi E. LTBP2 mutations cause Weill-Marchesani and Weill-Marchesani-like syndrome and affect disruptions in the extracellular matrix. Hum Mutat. 2012; 33:1182-7. [PMID: 22539340]
  7. Oklü R, Hesketh R. The latent transforming growth factor beta binding protein (LTBP) family. Biochem J. 2000; 352:601-10. [PMID: 11104663]
  8. Robinson PN, Godfrey M. The molecular genetics of Marfan syndrome and related microfibrillopathies. J Med Genet. 2000; 37:9-25. [PMID: 10633129]
  9. Gibson MA, Hatzinikolas G, Davis EC, Baker E, Sutherland GR, Mecham RP. Bovine latent transforming growth factor beta 1-binding protein 2: molecular cloning, identification of tissue isoforms, and immunolocalization to elastin-associated microfibrils. Mol Cell Biol. 1995; 15:6932-42. [PMID: 8524260]
  10. Ray K, Mukhopadhyay A, Acharya M. Recent advances in molecular genetics of glaucoma. Mol Cell Biochem. 2003; 253:223-31. [PMID: 14619973]
  11. Shields MBRR, Krupin T. Classification of the glaucomas. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. St. Louis (MO):Mosby-Year Book. 1996. p 717–25.
  12. Wiggs JL, Lynch S, Ynagi G, Maselli M, Auguste J, Del Bono EA, Olson LM, Haines JL. A genomewide scan identifies novel early-onset primary open-angle glaucoma loci on 9q22 and 20p12. Am J Hum Genet. 2004; 74:1314-20. [PMID: 15108121]
  13. Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR, Sunden SL, Nishimura D, Clark AF, Nystuen A, Nichols BE, Mackey DA, Ritch R, Kalenak JW, Craven ER, Sheffield VC. Identification of a gene that causes primary open angle glaucoma. Science. 1997; 275:668-70. [PMID: 9005853]
  14. Wiggs JL, Allingham RR, Hossain A, Kern J, Auguste J, DelBono EA, Broomer B, Graham FL, Hauser M, Pericak-Vance M, Haines JL. Genome-wide scan for adult onset primary open angle glaucoma. Hum Mol Genet. 2000; 9:1109-17. [PMID: 10767336]
  15. Pfeiffer RA, Buttinghaus K, Struck H. Partial trisomy 14 following a balanced reciprocal translocation t(14q-;21q+). Humangenetik. 1973; 20:187-9. [PMID: 4785169]
  16. Kousseff BG. Fahr disease: report of a family and a review. Acta Paediatr Belg. 1980; 33:57-61. [PMID: 7405589]
  17. Rotimi CN, Chen G, Adeyemo AA, Jones LS, Agyenim-Boateng K, Eghan BA, , Jr Zhou J, Doumatey A, Lashley K, Huang H, Fasanmade O, Akinsola FB, Ezepue F, Amoah A, Akafo S, Chen Y, Oli J, Johnson T. Genomewide scan and fine mapping of quantitative trait loci for intraocular pressure on 5q and 14q in West Africans. Invest Ophthalmol Vis Sci. 2006; 47:3262-7. [PMID: 16877390]
  18. Bayat B, Yazdani S, Alavi A, Chiani M, Chitsazian F, Tusi BK, Suri F, Narooie-Nejhad M, Sanati MH, Elahi E. Contributions of MYOC and CYP1B1 mutations to JOAG. Mol Vis. 2008; 14:508-17. [PMID: 18385784]
  19. Suri F, Kalhor R, Zargar SJ, Nilforooshan N, Yazdani S, Nezari H, Paylakhi SH, Narooie-Nejhad M, Bayat B, Sedaghati T, Ahmadian A, Elahi E. Screening of common CYP1B1 mutations in Iranian POAG patients using a microarray-based PrASE protocol. Mol Vis. 2008; 14:2349-56. [PMID: 19096718]
  20. Suri F, Yazdani S, Narooie-Nejhad M, Zargar SJ, Paylakhi SH, Zeinali S, Pakravan M, Elahi E. Variable expressivity and high penetrance of CYP1B1 mutations associated with primary congenital glaucoma. Ophthalmology. 2009; 116:2101-9. [PMID: 19744731]
  21. Ritch R, Schlotzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001; 45:265-315. [PMID: 11166342]
  22. Schlötzer-Schrehardt U, Naumann GO. Ocular and systemic pseudoexfoliation syndrome. Am J Ophthalmol. 2006; 141:921-37. [PMID: 16678509]
  23. Krumbiegel M, Pasutto F, Mardin CY, Weisschuh N, Paoli D, Gramer E, Zenkel M, Weber BH, Kruse FE, Schlotzer-Schrehardt U, Reis A. Exploring functional candidate genes for genetic association in german patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci. 2009; 50:2796-801. [PMID: 19182256]
  24. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods. 2010; 7:248-9. [PMID: 20354512]
  25. Schlötzer-Schrehardt U, Zenkel M, Kuchle M, Sakai LY, Naumann GO. Role of transforming growth factor-beta1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res. 2001; 73:765-80. [PMID: 11846508]
  26. Johnson M. 'What controls aqueous humour outflow resistance?'. Exp Eye Res. 2006; 82:545-57. [PMID: 16386733]
  27. Fan BJ, Wang DY, Lam DS, Pang CP. Gene mapping for primary open angle glaucoma. Clin Biochem. 2006; 39:249-58. [PMID: 16332362]
  28. Kuchtey J, Olson LM, Rinkoski T, Mackay EO, Iverson TM, Gelatt KN, Haines JL, Kuchtey RW. Mapping of the Disease Locus and Identification of ADAMTS10 As a Candidate Gene in a Canine Model of Primary Open Angle Glaucoma. PLoS Genet. 2011; 7:e1001306 [PMID: 21379321]
  29. Apte SS. A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. J Biol Chem. 2009; 284:31493-7. [PMID: 19734141]
  30. Fleenor DL, Shepard AR, Hellberg PE, Jacobson N, Pang IH, Clark AF. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest Ophthalmol Vis Sci. 2006; 47:226-34. [PMID: 16384967]
  31. Keller KE, Aga M, Bradley JM, Kelley MJ, Acott TS. Extracellular matrix turnover and outflow resistance. Exp Eye Res. 2009; 88:676-82. [PMID: 19087875]
  32. Tektas OY, Lutjen-Drecoll E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp Eye Res. 2009; 88:769-75. [PMID: 19114037]
  33. Nair KS, Hmani-Aifa M, Ali Z, Kearney AL, Ben Salem S, Macalinao DG, Cosma IM, Bouassida W, Hakim B, Benzina Z, Soto I, Soderkvist P, Howell GR, Smith RS, Ayadi H, John SW. Alteration of the serine protease PRSS56 causes angle-closure glaucoma in mice and posterior microphthalmia in humans and mice. Nat Genet. 2011; 43:579-84. [PMID: 21532570]
  34. Naumann GO, Schlotzer-Schrehardt U, Kuchle M. Pseudoexfoliation syndrome for the comprehensive ophthalmologist. Intraocular and systemic manifestations. Ophthalmology. 1998; 105:951-68. [PMID: 9627642]
  35. Zenkel M, Poschl E, von der Mark K, Hofmann-Rummelt C, Naumann GO, Kruse FE, Schlotzer-Schrehardt U. Differential gene expression in pseudoexfoliation syndrome. Invest Ophthalmol Vis Sci. 2005; 46:3742-52. [PMID: 16186358]
  36. Thorleifsson G, Magnusson KP, Sulem P, Walters GB, Gudbjartsson DF, Stefansson H, Jonsson T, Jonasdottir A, Stefansdottir G, Masson G, Hardarson GA, Petursson H, Arnarsson A, Motallebipour M, Wallerman O, Wadelius C, Gulcher JR, Thorsteinsdottir U, Kong A, Jonasson F, Stefansson K. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science. 2007; 317:1397-400. [PMID: 17690259]
  37. Pasutto F, Krumbiegel M, Mardin CY, Paoli D, Lammer R, Weber BH, Kruse FE, Schlotzer-Schrehardt U, Reis A. Association of LOXL1 common sequence variants in German and Italian patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci. 2008; 49:1459-63. [PMID: 18385063]
  38. Williams SE, Whigham BT, Liu Y, Carmichael TR, Qin X, Schmidt S, Ramsay M, Hauser MA, Allingham RR. Major LOXL1 risk allele is reversed in exfoliation glaucoma in a black South African population. Mol Vis. 2010; 16:705-12. [PMID: 20431720]
  39. Liu X, Zhao Y, Gao J, Pawlyk B, Starcher B, Spencer JA, Yanagisawa H, Zuo J, Li T. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat Genet. 2004; 36:178-82. [PMID: 14745449]
  40. Azmanov DN, Dimitrova S, Florez L, Cherninkova S, Draganov D, Morar B, Saat R, Juan M, Arostegui JI, Ganguly S, Soodyall H, Chakrabarti S, Padh H, Lopez-Nevot MA, Chernodrinska V, Anguelov B, Majumder P, Angelova L, Kaneva R, Mackey DA, Tournev I, Kalaydjieva L. LTBP2 and CYP1B1 mutations and associated ocular phenotypes in the Roma/Gypsy founder population. Eur J Hum Genet. 2011; 19:326-33. [PMID: 21081970]
  41. Robinson PN, Booms P, Katzke S, Ladewig M, Neumann L, Palz M, Pregla R, Tiecke F, Rosenberg T. Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies. Hum Mutat. 2002; 20:153-61. [PMID: 12203987]
  42. Hewett DR, Lynch JR, Child A, Sykes BC. A new missense mutation of fibrillin in a patient with Marfan syndrome. J Med Genet. 1994; 31:338-9. [PMID: 8071963]
  43. Sood S, Eldadah ZA, Krause WL, McIntosh I, Dietz HC. Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndrome. Nat Genet. 1996; 12:209-11. [PMID: 8563763]